FIGURE 3.

Progression‐free and overall survival of patients with marginal zone lymphoma who had been enrolled at the beginning of their first‐line treatment. (A) PFS since start of first‐line treatment for all patients included (n = 175) and (B) classified into either MALT MZL (n = 58) or non‐MALT MZL (n = 117); C) OS since start of first‐line treatment for all patients included (n = 175) and (D) classified into either MALT MZL (n = 58) or non‐MALT MZL (n = 117). CI, confidence interval; MALT, mucosa‐associated lymphoid tissue; MZL, marginal zone lymphoma; OS, overall survival; PFS, progression‐free survival